Last reviewed · How we verify
NCT03639844
BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 Study
trial testing rivogenlecleucel in Hurler Syndrome. No longer available.
Quick facts
| Lead sponsor | Bellicum Pharmaceuticals |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 2 locations across United States |
Drugs / interventions tested
- rivogenlecleucel — full drug profile →
- rimiducid — full drug profile →
Conditions studied
- Hurler Syndrome — all drugs for Hurler Syndrome →
- Inherited Metabolic Disorder — all drugs for Inherited Metabolic Disorder →
- Lysosomal Storage Disorder — all drugs for Lysosomal Storage Disorder →
- Metachromatic Leukodystrophy — all drugs for Metachromatic Leukodystrophy →
Sponsor
Bellicum Pharmaceuticals — full company profile →
Who can join
Adults 3 Months to 21, any sex, with Hurler Syndrome or Inherited Metabolic Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Providing access of BPX-501 gene modified T cells and rimiducid to pediatric patients who do not meet the eligibility criteria of the BP-U-004 study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Adoptive T Cell Therapy Following Haploidentical Hematopoietic Stem Cell Transplantation.
Zhang P, Tey SK. · · 2019 · cited 11× · PMID 31447852 · DOI 10.3389/fimmu.2019.01854
Verify or expand the search:
- PubMed search for NCT03639844
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of rivogenlecleucel
Trials testing the same drug.
- NCT03699475 — Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS · Phase 2, PHASE3 · terminated
Other recruiting trials for Hurler Syndrome
Currently open trials in the same condition.
- NCT02171104 — MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis · Phase 2 · active not recruiting
Other Bellicum Pharmaceuticals trials
Trials by the same sponsor.
- NCT04650451 — Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors · Phase 1 · suspended
- NCT03699475 — Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS · Phase 2, PHASE3 · terminated
- NCT02743611 — Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03639844 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bellicum Pharmaceuticals
- Last refreshed: 5 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03639844.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing